Cargando…
SAR by kinetics for drug discovery in protein misfolding diseases
To develop effective therapeutic strategies for protein misfolding diseases, a promising route is to identify compounds that inhibit the formation of protein oligomers. To achieve this goal, we report a structure−activity relationship (SAR) approach based on chemical kinetics to estimate quantitativ...
Autores principales: | , , , , , , , |
---|---|
Formato: | Online Artículo Texto |
Lenguaje: | English |
Publicado: |
National Academy of Sciences
2018
|
Materias: | |
Acceso en línea: | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC6187117/ https://www.ncbi.nlm.nih.gov/pubmed/30257937 http://dx.doi.org/10.1073/pnas.1807884115 |
_version_ | 1783362968713428992 |
---|---|
author | Chia, Sean Habchi, Johnny Michaels, Thomas C. T. Cohen, Samuel I. A. Linse, Sara Dobson, Christopher M. Knowles, Tuomas P. J. Vendruscolo, Michele |
author_facet | Chia, Sean Habchi, Johnny Michaels, Thomas C. T. Cohen, Samuel I. A. Linse, Sara Dobson, Christopher M. Knowles, Tuomas P. J. Vendruscolo, Michele |
author_sort | Chia, Sean |
collection | PubMed |
description | To develop effective therapeutic strategies for protein misfolding diseases, a promising route is to identify compounds that inhibit the formation of protein oligomers. To achieve this goal, we report a structure−activity relationship (SAR) approach based on chemical kinetics to estimate quantitatively how small molecules modify the reactive flux toward oligomers. We use this estimate to derive chemical rules in the case of the amyloid beta peptide (Aβ), which we then exploit to optimize starting compounds to curtail Aβ oligomer formation. We demonstrate this approach by converting an inactive rhodanine compound into an effective inhibitor of Aβ oligomer formation by generating chemical derivatives in a systematic manner. These results provide an initial demonstration of the potential of drug discovery strategies based on targeting directly the production of protein oligomers. |
format | Online Article Text |
id | pubmed-6187117 |
institution | National Center for Biotechnology Information |
language | English |
publishDate | 2018 |
publisher | National Academy of Sciences |
record_format | MEDLINE/PubMed |
spelling | pubmed-61871172018-10-15 SAR by kinetics for drug discovery in protein misfolding diseases Chia, Sean Habchi, Johnny Michaels, Thomas C. T. Cohen, Samuel I. A. Linse, Sara Dobson, Christopher M. Knowles, Tuomas P. J. Vendruscolo, Michele Proc Natl Acad Sci U S A Physical Sciences To develop effective therapeutic strategies for protein misfolding diseases, a promising route is to identify compounds that inhibit the formation of protein oligomers. To achieve this goal, we report a structure−activity relationship (SAR) approach based on chemical kinetics to estimate quantitatively how small molecules modify the reactive flux toward oligomers. We use this estimate to derive chemical rules in the case of the amyloid beta peptide (Aβ), which we then exploit to optimize starting compounds to curtail Aβ oligomer formation. We demonstrate this approach by converting an inactive rhodanine compound into an effective inhibitor of Aβ oligomer formation by generating chemical derivatives in a systematic manner. These results provide an initial demonstration of the potential of drug discovery strategies based on targeting directly the production of protein oligomers. National Academy of Sciences 2018-10-09 2018-09-26 /pmc/articles/PMC6187117/ /pubmed/30257937 http://dx.doi.org/10.1073/pnas.1807884115 Text en Copyright © 2018 the Author(s). Published by PNAS. https://creativecommons.org/licenses/by-nc-nd/4.0/ This open access article is distributed under Creative Commons Attribution-NonCommercial-NoDerivatives License 4.0 (CC BY-NC-ND) (https://creativecommons.org/licenses/by-nc-nd/4.0/) . |
spellingShingle | Physical Sciences Chia, Sean Habchi, Johnny Michaels, Thomas C. T. Cohen, Samuel I. A. Linse, Sara Dobson, Christopher M. Knowles, Tuomas P. J. Vendruscolo, Michele SAR by kinetics for drug discovery in protein misfolding diseases |
title | SAR by kinetics for drug discovery in protein misfolding diseases |
title_full | SAR by kinetics for drug discovery in protein misfolding diseases |
title_fullStr | SAR by kinetics for drug discovery in protein misfolding diseases |
title_full_unstemmed | SAR by kinetics for drug discovery in protein misfolding diseases |
title_short | SAR by kinetics for drug discovery in protein misfolding diseases |
title_sort | sar by kinetics for drug discovery in protein misfolding diseases |
topic | Physical Sciences |
url | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC6187117/ https://www.ncbi.nlm.nih.gov/pubmed/30257937 http://dx.doi.org/10.1073/pnas.1807884115 |
work_keys_str_mv | AT chiasean sarbykineticsfordrugdiscoveryinproteinmisfoldingdiseases AT habchijohnny sarbykineticsfordrugdiscoveryinproteinmisfoldingdiseases AT michaelsthomasct sarbykineticsfordrugdiscoveryinproteinmisfoldingdiseases AT cohensamuelia sarbykineticsfordrugdiscoveryinproteinmisfoldingdiseases AT linsesara sarbykineticsfordrugdiscoveryinproteinmisfoldingdiseases AT dobsonchristopherm sarbykineticsfordrugdiscoveryinproteinmisfoldingdiseases AT knowlestuomaspj sarbykineticsfordrugdiscoveryinproteinmisfoldingdiseases AT vendruscolomichele sarbykineticsfordrugdiscoveryinproteinmisfoldingdiseases |